We are international

The presentation will take place on June 9, 2010, in Barcelona, Spain.

The International Myeloma Foundation (IMF) is proud to award its prestigious Robert A. Kyle Lifetime Achievement Award for 2010 to Prof. Joan Bladé. The IMF's Robert A. Kyle Lifetime Achievement Award was established to honor an individual whose lifetime body of work furthers the ultimate goal of finding a cure for myeloma, a cancer of the bone marrow. The accolade is named after Dr. Robert A. Kyle, noted physician and founder of the Myeloma and Related Diseases Research Group at the Mayo Clinic in Rochester, Minnesota. Dr. Kyle himself was the first recipient of the award in 2003. Subsequently, the award has been presented to Dr. Bart Barlogie of the Myeloma Institute for Research and Therapy in Little Rock, Arkansas in 2004, Dr. Kenneth C. Anderson of the Dana Farber Cancer Institute in 2005, and Dr. Brian G.M. Durie of the Cedars Sinai Comprehensive Cancer Center in 2006, Prof. Heinz Ludwig in 2007, Prof. Mario Boccadoro in 2008 and Prof. Jean-Luc Harousseau in 2009.

Doctor Joan Bladé was born in Benissanet, Catalonia, Spain. He graduated from the Medical School of the University of Barcelona in 1976. Doctor Bladé completed his Fellowship at the Departments of Internal Medicine and Hematology at the Hospital Clínic of Barcelona between 1976 and 1980. In January 1981, he joined the staff at the Hematology Department of Hospital Clinic, where he is now a Senior Consultant and Director of the Amyloid and Myeloma Programs. Since 1981 Doctor Bladé has been particularly devoted to the care of patients with multiple myeloma and his research has been focused on clinical aspects, prognosis and treatment of this disease. Doctor Bladé spent one year as Visiting Clinician in the Dysproteinemia Clinic at the Mayo Clinic in Rochester, Minnesota. He was the Executive Secretary of the Spanish Cooperative PETHEMA Group between 1994 and 2001.He was co-founder of the PETHEMA Foundation, and co-founder of the Spanish Myeloma Group. Doctor Bladé chaired the group who developed the European Group and Marrow Transplantation (EBMT) response criteria for multiple myeloma, also known as the “Bladé Criteria”. He is reviewer of a number of outstanding scientific journals, he has published over 200 papers and more than 40 book chapters on both multiple myeloma and MGUS, and he is an active member of the International Myeloma Working Group (IMWG).

The presentation will take place on June 9, 2010, in Barcelona, Spain.  Presenting Sponsor: Celgene Corporation.

For information about sponsorship opportunities, please contact Suzanne Battaglia, at SBattaglia@myeloma.org, or (818) 487-7455.

 related articles